Oct 2, 2009 | BioSpace
Newly Published Phase III Data Show Novartis Oncology Drug...
Data published in the Journal of Clinical Oncology show that patients with advanced neuroendocrine tumors of the midgut who were treated with SandostatinA LAR Depot experienced a 66% reduction in risk of disease progression versus placebo .
Afinitor And Sandostatin LAR Phase II Data Show Advanced Pancreatic...
New data demonstrate that treatment with Afinitor in combination with Sandostatin LAR and Afinitor monotherapy may have the potential to stabilise tumour growth in patients with advanced pancreatic neuroendocrine tumours .
Novartis reports study results of Afinitor and Sandostatin LAR in...
Novartis reports study results of Afinitor and Sandostatin LAR in patients pancreatic neuroendocrine tumours M2Europharma on Wednesday, 24 June 2009 at 21:36 GMT 24 June 2009 - Swiss Novartis AG reported today results from a Phase II study of Afinitor Tablets in combination with Sandostatin LAR and Afinitor monotherapy in patients with pancreatic ...
Also on Topix